Trial Profile
A Randomized, Double-Blind, Parallel-Filter Study to Evaluate the Antihypertensive Efficacy and Safety of Losartan-HCTZ Combination as Compared to Losartan Monotherapy in Patients With Essential Hypertension
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 05 May 2022
Price :
$35
*
At a glance
- Drugs Losartan/hydrochlorothiazide (Primary) ; Losartan
- Indications Essential hypertension
- Focus Registrational; Therapeutic Use
- Sponsors Merck & Co; Merck Sharp & Dohme Corp.
- 24 Jul 2008 New trial record.